Akari Highlights ASCO Data, Plans AKTX-101 Phase 1 Trial by Mid-2027

Akari Therapeutics released a CEO Corner segment discussing insights from the 2026 ASCO Annual Meeting and the company's strategic position in the evolving ADC landscape. CEO Abizer Gaslightwala highlighted the growing importance of novel ADC payloads for difficult-to-treat KRAS-driven cancers and the industry's shift towards "ADC 2.0." The segment featured preclinical data presented at ASCO, demonstrating synergy between Akari's PH1 spliceosome-modulating payload and a KRAS inhibitor in pancreatic cancer models. The company also outlined anticipated milestones, including the planned initiation of its Phase 1 first-in-human clinical trial for lead candidate AKTX-101 by mid-2027.